Provided by Tiger Trade Technology Pte. Ltd.

Vanda Pharmaceuticals

5.28
-0.1000-1.86%
Post-market: 5.26-0.0200-0.38%19:36 EDT
Volume:656.79K
Turnover:3.50M
Market Cap:319.24M
PE:-1.14
High:5.42
Open:5.42
Low:5.27
Close:5.38
52wk High:9.94
52wk Low:4.27
Shares:60.46M
Float Shares:51.04M
Volume Ratio:0.72
T/O Rate:1.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6291
EPS(LYR):-3.7413
ROE:-77.81%
ROA:-22.38%
PB:1.45
PE(LYR):-1.41

Loading ...

Vanda Pharmaceuticals announces commercial availability for Nereus

TIPRANKS
·
May 02

Vanda Pharmaceuticals: Standard List Price of $255 per Dose for Nereus

THOMSON REUTERS
·
May 02

Vanda Pharmaceuticals: Patients With Valid Prescription Can Access Nereus at Cash-Pay Price of $85 per Dose

THOMSON REUTERS
·
May 02

Vanda Pharmaceuticals Announces U.S. Commercial Availability of Nereus™ (Tradipitant), the First New Pharmacologic Treatment for People With Motion Sickness in More Than 40 Years

THOMSON REUTERS
·
May 02

Vanda Pharma to report first-quarter results after market close, host conference call

Reuters
·
Apr 30

Vanda publishes phase III imsidolimab trial results for generalized pustular psoriasis in NEJM Evidence

Reuters
·
Apr 29

Vanda Pharmaceuticals director Duncan files initial beneficial ownership statement

Reuters
·
Apr 25

Vanda Pharmaceuticals announces annual shareholder meeting webcast

Reuters
·
Apr 24

Vanda Pharmaceuticals Adds Independent Director to Strengthen Board

TIPRANKS
·
Apr 23

Vanda Pharmaceuticals appoints Charles Duncan to board of directors

Reuters
·
Apr 23

Vanda Pharmaceuticals Appoints DR. Charles Duncan to Its Board of Directors

THOMSON REUTERS
·
Apr 23

Vanda files Form 3 for Senior VP, Medical Director Christos Polymeropoulos

Reuters
·
Apr 14

Vanda VP, Chief People Officer Scott Laverne Howell files initial beneficial ownership statement

Reuters
·
Apr 14

BUZZ-U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman

Reuters
·
Apr 10

Sector Update: Health Care Stocks Advance in Afternoon Trading

MT Newswires Live
·
Apr 10

Vanda urges FDA to drop proposal extending statutory drug review timelines

Reuters
·
Apr 09

Vanda Pharmaceuticals Inc - Proposal Would Eliminate FDA 180-Day Nda Review Requirement

THOMSON REUTERS
·
Apr 09

Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal From FY 2027 Legislative Agenda That Would Extend Drug Review Timelines

THOMSON REUTERS
·
Apr 09

Vanda Pharmaceuticals: Undervalued GLP-1 Adjunct Opportunity Driven by Tradipitant’s Pivotal Thetis Trial

TIPRANKS
·
Apr 09

Vanda starts Thetis trial of NEREUS to curb GLP-1 therapy vomiting

Reuters
·
Apr 09